← Back to Search

Mitochondrial Antioxidant

MitoQ for Cardiovascular Disease (MOVHS Trial)

Led By Austin T Robinson, PhD
Research Sponsored by Auburn University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Screening 3 weeks
Treatment Varies
Follow Up changes from before and after 8 week supplementation and placebo
Awards & highlights

MOVHS Trial Summary

This trial will assess if a mitochondrial antioxidant (MitoQ) can reduce CVD risk among Black Americans, who are disproportionately affected by CVD. Researchers will measure blood pressure, vascular function, and biomarkers of kidney function before & after 8 weeks of MitoQ/placebo.

Who is the study for?
This trial is for middle-aged and older adults (45-75 years old) who are generally healthy but at risk of cardiovascular disease, particularly Black Americans. Participants must not have medical conditions that prevent exercise, giving blood, or allergies to MitoQ ingredients. They should have a BMI under 40 Kg/m2 and blood pressure below 150/90 mmHg without a history of serious diseases like cancer, diabetes, or heart issues.Check my eligibility
What is being tested?
The study tests if the antioxidant MitoQ can reduce oxidative stress and improve vascular health over an 8-week period in individuals at risk for cardiovascular disease. It involves daily consumption of MitoQ compared to a placebo while also considering social factors and health behaviors.See study design
What are the potential side effects?
While specific side effects aren't listed here, participants will be monitored for any adverse reactions due to MitoQ which could include typical supplement-related side effects such as digestive discomfort or allergic reactions.

MOVHS Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline (pre-intervention)
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline (pre-intervention) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Changes in blood biomarkers of nitric oxide bioavailability
Changes in blood pressure reactivity
Changes in circulating reactive oxygen species
+3 more
Secondary outcome measures
Habitual dietary intake
Mental health - depression
Objective sleep duration
+11 more

MOVHS Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: MitoQExperimental Treatment1 Intervention
8-week MitoQ supplementation (20 mg daily capsule).
Group II: PlaceboPlacebo Group1 Intervention
8-week placebo matched in appearance to MitoQ supplementation (20 mg daily capsule).
First Studied
Drug Approval Stage
How many patients have taken this drug
Completed Phase 2

Find a Location

Who is running the clinical trial?

Auburn UniversityLead Sponsor
72 Previous Clinical Trials
14,345 Total Patients Enrolled
Austin T Robinson, PhDPrincipal InvestigatorKinesiology Building
3 Previous Clinical Trials
190 Total Patients Enrolled

Media Library

MitoQ (Mitochondrial Antioxidant) Clinical Trial Eligibility Overview. Trial Name: NCT05561556 — N/A
Cardiovascular Disease Research Study Groups: Placebo, MitoQ
Cardiovascular Disease Clinical Trial 2023: MitoQ Highlights & Side Effects. Trial Name: NCT05561556 — N/A
MitoQ (Mitochondrial Antioxidant) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05561556 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are adults of the requisite age being enrolled in this experiment?

"The age range for this study is 45 - 75 years old."

Answered by AI

Is participation in this study open to the public at this time?

"According to clinicaltrials.gov, this medical research is presently recruiting patients and has been since December 6th 2022. The trial was last amended on January 31st 2023."

Answered by AI

How many participants have been approved to take part in the experiment?

"Affirmative, according to clinicaltrials.gov the trial is actively recruiting participants as of now. It was first posted on December 6th 2022 and most recently revised on January 31st 2023. The study requires 60 individuals from a single medical site."

Answered by AI

What are the key aims of this research project?

"This 8-week trial will measure changes in nitric oxide bioavailability as its primary outcome. Secondary outcomes include assessing levels of subjective sleepiness using the Epworth Sleepiness Scale, gauging an individual's chronotype through the Munich Chronotype Questionnaire, and quantifying insomnia severity with the Insomnia Severity Index."

Answered by AI

What characteristics are sought in participants of this research endeavor?

"This trial is currently accepting up to 60 volunteers aged 45-75 with high blood pressure. In addition, they must display a BMI of less than 40 Kg/m2, be free from metabolic and cardiovascular diseases, have no medical conditions which impede them from exercising or donating plasma, and not suffer any allergies linked to MitoQ substances for eligibility."

Answered by AI
~38 spots leftby Aug 2026